- 专利标题: Anti-GITR antibodies and methods of use thereof
-
申请号: US16355268申请日: 2019-03-15
-
公开(公告)号: US10829559B2公开(公告)日: 2020-11-10
- 发明人: Volker Seibert , Olivier Léger , Marc Van Dijk , Taha Merghoub , David Schaer , Gerd Ritter , Takemasa Tsuji
- 申请人: Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
- 申请人地址: US MA Lexington US NY New York CH Zurich
- 专利权人: Agenus Inc.,Memorial Sloan-Kettering Cancer Center,Ludwig Institute for Cancer Research Ltd.
- 当前专利权人: Agenus Inc.,Memorial Sloan-Kettering Cancer Center,Ludwig Institute for Cancer Research Ltd.
- 当前专利权人地址: US MA Lexington US NY New York CH Zurich
- 代理机构: Lathrop GPM LLP
- 代理商 Andrew T. Wilkins
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K39/00 ; G01N33/50 ; A61K35/17
摘要:
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
公开/授权文献
- US20190309082A1 ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF 公开/授权日:2019-10-10
信息查询